Navigation Links
Acute Lymphocytic Leukemia: Impressive Results With the Monoclonal Antibody Blinatumomab in Patients With Refractory Disease
Date:6/15/2012

AMSTERDAM, June 15, 2012 /PRNewswire/ --

At the 17th Congress of the European Hematology Association in Amsterdam Professor Max Topp of the University of Wuerzberg in Germany presents the impressive results with a bispecific antibody for Acute Lymphoblastic Leukemia patients.

The Phase 2 dose-ranging study MT103-206 evaluated the efficacy, safety and tolerability of blinatumomab in adult patients with B-precursor Acute Lymphoblastic Leukemia who had relapsed following treatment with standard front-line chemotherapy or allogeneic stem cell transplant. Patients received blinatumomab for 28 days followed by two weeks off therapy over a six week treatment cycle, for up to five treatment cycles. Patients received a continuous intravenous infusion of blinatumomab at an initial dose of five or 15 micrograms/m2 per day, escalating to 30 micrograms for the remainder of the treatment. The primary endpoint of the study was the rate of complete remission (CR) and complete remission with partial hematologic recovery (CRh*). Secondary endpoints included molecular response rate, duration of response and overall survival. All 36 patients were evaluable for efficacy and safety.

Twenty-six of the 36 patients (72%) treated with blinatumomab across all of the tested doses and schedules achieved a CR/CRh*. All but two patients achieved a molecular response, meaning there was no evidence of leukemic cells by polymerase chain reaction. The most common adverse events were pyrexia, headache and tremor. Medically important safety events were reversible cytokine release syndrome and CNS adverse events.

At the time of the analysis, median survival was 9.0 (8.2, 15.8) months with a median follow-up period of 10.7 months. The median duration of response in the 26 patients who responded to treatment was 8.9 months.

About the EHA Annual Congress

After 16 congresses and constantly increasing number of delegates, the 17th'/>"/>

SOURCE European Hematology Association
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Nautilus Neurosciences, Inc. Announces a New Approval for CAMBIA® for the Acute Treatment of Migraine
2. CSL Behring Study Confirms Early Treatment with Berinert® Provides Faster Resolution of Acute Hereditary Angioedema Symptoms
3. MarketsandMarkets: Acute Myeloid Leukemia Therapeutics Market in G8 Countries Worth $1.67 Billion by 2020
4. Start of Phase IIa Study in Acute Lung Injury Patients Marks Development Milestone
5. MarketsandMarkets: Acute Lymphocytic Leukemia Therapeutics Market worth $3.88 Billion by 2020
6. TetraLogic Pharmaceuticals Announces Initiation of a Phase 1/2 Clinical Trial of TL32711 in Patients with Acute Myelogenous Leukemia (AML)
7. How Malignant Cells in Patients With Chronic Lymphocytic Leukemia Escape T Cell Recognition and Attack
8. MarketsandMarkets: Chronic Lymphocytic Leukemia Therapeutics Market Worth $2.2 Billion by 2020
9. China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2012
10. Sanofi and Regeneron Announce Publication of Positive Phase 2 Results for Lipid-Lowering PCSK9 Antibody in The Lancet
11. GeneLink Reports First Quarter 2012 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... San Francisco, CA (PRWEB) August 20, 2014 ... Medicine Conference is being held on October 29-30 ... fresh perspectives from industry, academic and government researchers and ... remaining in the space. , In the twelve ... than one hundred therapies have been introduced with pharmacogenetic ...
(Date:8/20/2014)... your ear could improve the health of your heart, ... of Leeds used a standard TENS machine like those ... to the tragus, the small raised flap at the ... ear canal. , The stimulation changed the influence of ... nervous signals that can drive failing hearts too hard. ...
(Date:8/19/2014)... Piscataway, NJ (PRWEB) August 20, 2014 ... engineering and regenerative medicine is an inadequate vascular ... engineered constructs and decellularized tissues is critical for ... Researchers have attempted to mitigate deficiencies in vascularization ... including adding scaffold bioactivity, optimizing scaffold design and ...
(Date:8/19/2014)... , Aug. 19, 2014 A Geisinger researcher ... nominated for a Centers for Disease Control and Prevention ... major public health concern. Joseph Boscarino ... one of a team of researchers nominated for the ... Shepard Science Award for Data Methods and Study Design. ...
Breaking Biology Technology:6th Annual Personalized and Precision Medicine Conference Bringing Together Thought Leaders to Discuss Clinical Implementation, Dx Reimbursement, Big Data, and Sequencing 2'Tickling' your ear could be good for your heart 2Vascularization in Tissue Engineering Highlighted at 12th New Jersey Symposium on Biomaterials Science 2Geisinger investigator nominated for federal award 2Geisinger investigator nominated for federal award 3
... Provides HIV-Resistant Immune CellsRICHMOND, Calif., Feb. 3 Sangamo ... that its collaborators at the University of Pennsylvania ... evaluate SB-728-T for the treatment of HIV/AIDS. Based on ... has been shown in an animal model of ...
... face of a recession is no small feat for any company. ... Sudberg called "being in the right place at the right time" and ... ... CA (PRWEB) February 2, 2009 -- Sidney Sudberg, Founder, CEO and Chief ...
... 2 Since the cloning of Dolly the ... has been considered a promising way to generate human, patient-specific ... eggs has led to efforts to substitute animal oocytes. However, ... Volume 11, Number 2, 2009 issue of Cloning and ...
Cached Biology Technology:Sangamo BioSciences Initiates Phase 1 Trial of CCR5-ZFP Therapeutic to Treat HIV/AIDS 2Sangamo BioSciences Initiates Phase 1 Trial of CCR5-ZFP Therapeutic to Treat HIV/AIDS 3Sangamo BioSciences Initiates Phase 1 Trial of CCR5-ZFP Therapeutic to Treat HIV/AIDS 4Sangamo BioSciences Initiates Phase 1 Trial of CCR5-ZFP Therapeutic to Treat HIV/AIDS 5Sangamo BioSciences Initiates Phase 1 Trial of CCR5-ZFP Therapeutic to Treat HIV/AIDS 6Sangamo BioSciences Initiates Phase 1 Trial of CCR5-ZFP Therapeutic to Treat HIV/AIDS 7Alkemists Labs Wins Nutrition Business Journal's 2008 Industry Growth Award 2Alkemists Labs Wins Nutrition Business Journal's 2008 Industry Growth Award 3Animal Eggs Not Suitable Substitutes to Produce Stem Cells 2Animal Eggs Not Suitable Substitutes to Produce Stem Cells 3
(Date:8/20/2014)... Using population-based screening outcomes of approximately 3 million ... four researchers at the University of Massachusetts Medical School, ... (SCID) can be successfully implemented across public health newborn ... in the Aug. 20 issue of the Journal ... showed the rate of SCID in newborns is higher ...
(Date:8/20/2014)... Ore. -- When are athletes who have suffered concussions ... Oregon study has found that high school athletes who ... 60 days experience a significant regression in their abilities ... The regression, as seen in changes in their balance ... 19 athletes. Ten of the 12 had returned to ...
(Date:8/20/2014)... bags could one day be made out of cocoa, ... now reporting. The novel process they developed and their ... agricultural and plastic waste problems, appear in the ACS ... Bayer and colleagues at the Italian Institute of Technology ... 2012, its production reached 288 million tons worldwide, but ...
Breaking Biology News(10 mins):Newborn screening expansion offers early diagnosis and treatment to infants with SCID 2Newborn screening expansion offers early diagnosis and treatment to infants with SCID 3Recovery reversal seen in Oregon study of returning concussed athletes 2Recovery reversal seen in Oregon study of returning concussed athletes 3
... SPRING HARBOR, N.Y. (Nov. 12, 2008) For ... for written exams on theoretical concepts, it can be ... skills used in the clinic. The third edition ... for these daunting practical-skills tests, Clinical Skills for ...
... is proud to acknowledge the work of 12 outstanding ... new ideas, recognize leadership in gerontological teaching and service, ... award presentations will take place at GSA,s 61st Annual ... 2008, in National Harbor, MD , at the ...
... November 09, 2008─Bronx, NY─ In a breakthrough study appearing ... researchers at Albert Einstein College of Medicine of Yeshiva ... viewing individual breast cancer cells for several days at ... Lipper Biophotonics Center, provides detail on how cancer cells ...
Cached Biology News:New book helps medical students master clinical skills 2GSA congratulates 2008 award winners 2GSA congratulates 2008 award winners 3Einstein researchers develop a new way to study how breast cancer spreads 2Einstein researchers develop a new way to study how breast cancer spreads 3
BD Biocoat Matrigel Matrix Thin Layer 35 mm Culture Dishes...
... ICE-family proteases/caspases initiates apoptosis in mammalian cells. ... Kit provides a simple and convenient means ... cytometry in intact cells. The assay ... residues linked to rhodamine 110 (D2R), a ...
... antibiotic-based selection system for recombinant identification. Recombinant ... the need for costly color screening. This ... 100% accuracy in recombinant selection. pLivSelect is ... picking. This cloning kit can be used ...
... revolutionizes imaging software for the microscopy ... microscopes, cameras, components and peripherals with ... tools. Its intuitive interface simplifies workflow ... while providing powerful features such as ...
Biology Products: